8-K: Lantheus Holdings Anticipates SPLASH Trial Data Release in October

Lantheus Holdings expects to release data from its Phase 3 SPLASH trial for PNT2002 in October 2024, based on reaching 75% of the protocol-specified overall survival events.

Summary

• Lantheus Holdings announced that it anticipates releasing data from the SPLASH trial in October 2024.
• The SPLASH trial is a Phase 3 study evaluating PNT2002 in patients with PSMA-expressing mCRPC who have progressed on ARPI therapy and are not eligible for chemotherapy.
• The trial randomized 412 patients across North America, Europe, and the United Kingdom, with a 2:1 randomization favoring PNT2002 over abiraterone or enzalutamide.
• Patients in the control arm who experienced disease progression had the option to crossover to receive PNT2002, with 84.6% of those with progressive disease doing so.
• The primary endpoint of the study is radiographic progression-free survival, and patients will be followed for up to 5 years.
• The data release is expected when 75% of the protocol-specified target overall survival events have been reached.
• The trial was conducted across the United States, Canada, Europe, and the United Kingdom, with 80% of patients residing in North America and approximately 10% being Black or African American.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the anticipation of trial data release, but tempered by the inherent risks and uncertainties associated with clinical trials and regulatory approvals.

Positives

• The SPLASH trial has reached a significant milestone with 75% of the target overall survival events reached, triggering the data release.
• A high percentage of patients in the control arm with progressive disease crossed over to receive PNT2002, indicating potential efficacy.
• The trial has a broad geographic reach, including North America, Europe, and the United Kingdom, which could support wider adoption if successful.
• The trial includes a diverse patient population, with approximately 10% of participants being Black or African American.

Risks

• The outcome of the SPLASH trial after full data is available could differ from expectations.
• There is a risk of delay or failure to obtain regulatory approval for PNT2002 from the FDA and other authorities.
• There are risks associated with successfully launching PNT2002 as a commercial product.
• Market and patient receptivity to PNT2002 as a radiopharmaceutical therapy is uncertain.
• The existence of competing products and therapies could impact the success of PNT2002.
• Lantheus' ability to obtain and maintain adequate coding, coverage, and payment for PNT2002 is a risk.
• The intellectual property protection of PNT2002 is a risk.
• POINT Biopharma's ability to successfully develop and scale manufacturing capabilities to support the launch of PNT2002 is a risk.

Future Outlook

Lantheus anticipates releasing data from the SPLASH trial in October 2024, which will be a key factor in determining the future of PNT2002. The company's future success depends on the outcome of the trial, regulatory approvals, and market adoption.

Industry Context

This announcement is significant in the context of the growing interest in radiopharmaceutical therapies for cancer treatment. The SPLASH trial results will be closely watched by the oncology community and investors, as they could impact the competitive landscape for prostate cancer treatments.

Comparison to Industry Standards

• The SPLASH trial's design, with a crossover option for the control arm, is becoming more common in oncology trials to address ethical concerns and improve patient outcomes.
• The use of 177Lu-based therapies is a growing trend in radiopharmaceutical treatments, with companies like Novartis (Pluvicto) also developing similar therapies for prostate cancer.
• The trial's focus on PSMA-expressing mCRPC aligns with the industry's focus on targeted therapies for specific cancer subtypes.
• The geographic scope of the trial, including North America, Europe, and the United Kingdom, is typical for late-stage clinical trials aiming for global regulatory approvals.

Stakeholder Impact

• Shareholders will be impacted by the SPLASH trial results and the potential commercial success of PNT2002.
• Patients with mCRPC may benefit from a new treatment option if PNT2002 is approved.
• Employees of Lantheus may be affected by the company's performance and the success of PNT2002.
• Healthcare providers will be impacted by the availability of a new treatment option for prostate cancer.

Next Steps

• Lantheus will release data from the SPLASH trial in October 2024.
• The company will continue to pursue regulatory approvals for PNT2002.
• Lantheus will monitor the market and patient receptivity to PNT2002.

Key Dates

Keywords

PNT2002, SPLASH trial, mCRPC, radiopharmaceutical therapy, PSMA, Lantheus Holdings, clinical trial, oncology, prostate cancer